Trials / Withdrawn

WithdrawnNCT00881673

To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge (CAC)

Status: Withdrawn
Phase: Phase 2
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Alcon Research · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Accepted

Summary

The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).

Conditions

Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	AL38583 Ophthalmic Solution	Topical ophthalmic
DRUG	Maxidex	Topical ophthalmic
DRUG	Vehicle	AL38583 Vehicle

Timeline

Start date: 2009-05-01
Primary completion: 2009-05-01
Completion: 2009-05-01
First posted: 2009-04-15
Last updated: 2012-03-06

Source: ClinicalTrials.gov record NCT00881673. Inclusion in this directory is not an endorsement.